{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:33:39Z","timestamp":1766136819022,"version":"3.48.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.lansea.2025.100699","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:05:09Z","timestamp":1764327909000},"page":"100699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Delandistrogene Moxeparvovec gene therapy for Duchenne muscular dystrophy: the way forward in South Asian countries"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-4691","authenticated-orcid":false,"given":"Priyanka","family":"Madaan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jithangi","family":"Wanigasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5194-9951","authenticated-orcid":false,"given":"Jitendra Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lansea.2025.100699_bib1","series-title":"StatPearls","article-title":"Duchenne muscular dystrophy. 2023 Jul 10","author":"Venugopal","year":"2025"},{"key":"10.1016\/j.lansea.2025.100699_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.lansea.2025.100699_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne Muscular Dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lansea.2025.100699_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.lansea.2025.100699_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.lansea.2025.100699_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40120-024-00685-8","article-title":"Caregiver global impression observations from EMBARK: a phase 3 study evaluating Delandistrogene Moxeparvovec in ambulatory patients with Duchenne muscular dystrophy","volume":"14","author":"McDonald","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.lansea.2025.100699_bib8","article-title":"The landscape of infantile epileptic spasms syndrome in South Asia: peculiarities, challenges, and way forward","volume":"12","author":"Sahu","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"10.1016\/j.lansea.2025.100699_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0028-3886.222881","article-title":"Natural history of a cohort of Duchenne muscular dystrophy children seen between 1998 and 2014: an observational study from South India","volume":"66","author":"Singh","year":"2018","journal-title":"Neurol India"},{"key":"10.1016\/j.lansea.2025.100699_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.braindev.2019.12.005","article-title":"Clinical practice with steroid therapy for Duchenne muscular dystrophy: an expert survey in Asia and Oceania","volume":"42","author":"Takeuchi","year":"2020","journal-title":"Brain Dev"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225001702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:25:06Z","timestamp":1766136306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368225001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":9,"alternative-id":["S2772368225001702"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100699","relation":{},"ISSN":["2772-3682"],"issn-type":[{"type":"print","value":"2772-3682"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delandistrogene Moxeparvovec gene therapy for Duchenne muscular dystrophy: the way forward in South Asian countries","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100699"}}